Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 226

1.

Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma.

Vatsyayan R, Singhal J, Nagaprashantha LD, Awasthi S, Singhal SS.

Mol Carcinog. 2013 Jan;52(1):39-48. doi: 10.1002/mc.20875. Epub 2011 Oct 17.

2.
3.

The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status.

Zauli G, Celeghini C, Melloni E, Voltan R, Ongari M, Tiribelli M, di Iasio MG, Lanza F, Secchiero P.

Haematologica. 2012 Nov;97(11):1722-30. doi: 10.3324/haematol.2012.062083. Epub 2012 Jun 11.

4.

Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma.

Yuen JS, Sim MY, Sim HG, Chong TW, Lau WK, Cheng CW, Ong RW, Huynh H.

Int J Oncol. 2012 Aug;41(2):712-20. doi: 10.3892/ijo.2012.1494. Epub 2012 May 23.

PMID:
22641227
5.
6.

MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.

Saha MN, Jiang H, Jayakar J, Reece D, Branch DR, Chang H.

Cancer Biol Ther. 2010 Jun 1;9(11):936-44. Epub 2010 Jun 27.

PMID:
20418664
7.

Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1.

Ray RM, Bhattacharya S, Johnson LR.

Apoptosis. 2011 Jan;16(1):35-44. doi: 10.1007/s10495-010-0538-0.

PMID:
20812030
8.
9.
10.

Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.

Ou DL, Shen YC, Liang JD, Liou JY, Yu SL, Fan HH, Wang DS, Lu YS, Hsu C, Cheng AL.

Clin Cancer Res. 2009 Sep 15;15(18):5820-8. doi: 10.1158/1078-0432.CCR-08-3294. Epub 2009 Sep 8.

11.

Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.

Ambrosini G, Sambol EB, Carvajal D, Vassilev LT, Singer S, Schwartz GK.

Oncogene. 2007 May 24;26(24):3473-81. Epub 2006 Dec 4.

PMID:
17146434
12.

Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells.

Endo S, Yamato K, Hirai S, Moriwaki T, Fukuda K, Suzuki H, Abei M, Nakagawa I, Hyodo I.

Cancer Sci. 2011 Mar;102(3):605-13. doi: 10.1111/j.1349-7006.2010.01821.x. Epub 2011 Jan 12.

13.

Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma.

Katz SI, Zhou L, Chao G, Smith CD, Ferrara T, Wang W, Dicker DT, El-Deiry WS.

Cancer Biol Ther. 2009 Dec;8(24):2406-16. Epub 2009 Dec 2.

14.

Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).

Drakos E, Singh RR, Rassidakis GZ, Schlette E, Li J, Claret FX, Ford RJ Jr, Vega F, Medeiros LJ.

Leukemia. 2011 May;25(5):856-67. doi: 10.1038/leu.2011.28. Epub 2011 Mar 11.

15.

Nutlin-3, a small-molecule MDM2 inhibitor, sensitizes Caki cells to TRAIL-induced apoptosis through p53-mediated PUMA upregulation and ROS-mediated DR5 upregulation.

Park EJ, Choi KS, Yoo YH, Kwon TK.

Anticancer Drugs. 2013 Mar;24(3):260-9. doi: 10.1097/CAD.0b013e32835c0311.

PMID:
23187459
16.

MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.

Wang J, Zheng T, Chen X, Song X, Meng X, Bhatta N, Pan S, Jiang H, Liu L.

J Gastroenterol Hepatol. 2011 Feb;26(2):371-7. doi: 10.1111/j.1440-1746.2010.06440.x.

PMID:
21261729
17.

Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy.

Inoue H, Hwang SH, Wecksler AT, Hammock BD, Weiss RH.

Cancer Biol Ther. 2011 Nov 1;12(9):827-36. doi: 10.4161/cbt.12.9.17680. Epub 2011 Nov 1.

19.
20.

Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo.

Wei G, Wang M, Hyslop T, Wang Z, Carr BI.

Int J Cancer. 2010 Dec 15;127(12):2949-58. doi: 10.1002/ijc.25498.

Supplemental Content

Support Center